Investigational drug · Phase 3
SYS6002
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
5 still active
All registered trials
5
Any phase or sponsor naming "SYS6002"
First trial start
2025
Aug 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYS6002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Urothelial Carcinoma
- Cervical Cancer
- Advanced Solid Tumors
- Head and Neck Squamous Cell Carcinoma
- Advanced Urothelial Carcinoma
Approved drugs for the same conditions: Bladder and urothelial cancer · Head and neck cancer · Cervical cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SYS6002" as an intervention, largest first.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Industry
NCT07241936 · 444 participants (planned) · Start Nov 13, 2025 · Primary completion Oct 30, 2027
Drug: sirolimus (albumin-bound); DP303c and 3 more · For: Advanced Solid Tumors
Sites: Shanghai, China
- SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCCPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT06989671 · 430 participants (planned) · Start Aug 30, 2025 · Primary completion Dec 30, 2027
Drug: JMT101; SYS6002 and 1 more · For: Head and Neck Squamous Cell Carcinoma
- SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical CancerPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07230626 · 412 participants (planned) · Start Nov 20, 2025 · Primary completion Jan 1, 2028
Drug: SYS6002; Investigator's Choice of Chemotherapy · For: Cervical Cancer
- SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial CarcinomaPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07526792 · 406 participants (planned) · Start Jun 20, 2026 · Primary completion Jun 1, 2029
Drug: SYS6002; Investigator's Choice of Chemotherapy · For: Urothelial Carcinoma
- SYS6002 vs PADCEV in Patients With Advanced Urothelial CarcinomaPivotal-lookingNot yet recruiting
CSPC Megalith Biopharmaceutical Co.,Ltd.Industry
NCT07374549 · 100 participants (planned) · Start Jun 20, 2026 · Primary completion Jun 1, 2028
Drug: SYS6002; enfortumab vedotin · For: Advanced Urothelial Carcinoma
Newest research
PubMed records naming it or its code names, newest first.
- CRB-701: A Second-generation Nectin-4-Targeted Antibody-Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors.
Sun Z, Dan M, Lv L, et al. · Cancer Res Commun 2026
Also in development for Urothelial Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- BudigalimabABBV-181Phase 36 trials
AbbVie · Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET
- Cretostimogene GrenadenorepvecCG0070Phase 34 trials
CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer
- GimistotugBGB-A445Phase 34 trials
BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma
- LivmoniplimabABBV-151Phase 34 trials
AbbVie · Hepatocellular Carcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer
- SI-B003Phase 210 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.